Clinical trials: Sirolimus, completed
Brain and Central Nervous System Tumors, Metastatic Cancer
A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors
RATIONALE: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more…
- Trial name
- NCT00784914
- Testing
- temsirolimus, pharmacological study, cytokine levels
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- City of Hope Medical Center
Posttraumatic Stress Disorder
Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory
The purpose of the proposed study is to determine if pairing reactivation of a traumatic memory with a single administration of Rapamycin (e.g., Sirolimus) in men with combat-related Posttraumatic Stress Disorder leads to a…
- Trial name
- NCT01449955
- Testing
- Rapamycin
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- University of Texas Southwestern Medical Center
Low-grade Gliomas
Tarceva/Rapamycin for Children With Low-grade Gliomas With or Without Neurofibromatosis Type 1 (NF1)
This study will evaluate the feasibility of combining two drugs, Tarceva (an anti-EGFR agent), and Rapamycin (an mTOR inhibitor), in children with progressive low-grade gliomas who have failed initial conventional treatment.
- Trial name
- NCT00901849
- Testing
- Tarceva and Rapamycin
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Roger Packer
Kidney Cancer
Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer
RATIONALE: Everolimus and imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Everolimus may also block blood flow to the tumor.
- Trial name
- NCT00331409
- Testing
- Everolimus, imatinib mesylate
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- OHSU Knight Cancer Institute
Kidney Failure, Graft Rejection
Study Evaluating Two Different Sirolimus-based Immunosuppressive Regimens in Elderly Kidney Transplant Recipients
The purpose of this study is to test two different sirolimus-based immunosuppressive regimens for elderly kidney transplant recipients.
- Conditions
- Kidney Failure, Graft Rejection, Aged
- Trial name
- NCT00254709
- Testing
- Sirolimus
- Volunteers
- 66 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Advanced Malignant Solid Neoplasm
MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations
This phase II trial studies molecular profiling-based assignment of cancer therapy (MPACT) in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with…
- Trial name
- NCT01827384
- Testing
- Adavosertib, Carboplatin, Everolimus
- Where
- 8 sites in United States
- Volunteers
- 208 people
- Sponsor
- National Cancer Institute (NCI)
Neurofibromatosis Type 2, Vestibular Schwannomas
Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas
The primary objective is to estimate the proportions of vestibular schwannomas (VS) and meningiomas after 10 days of exposure to the study drug RAD001 at a dose of 10 mg daily, as determined by immunohistochemistry.
- Conditions
- Neurofibromatosis Type 2, Vestibular Schwannomas, Meningiomas
- Trial name
- NCT01880749
- Testing
- RAD001
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- NYU Langone Health
Neurofibromatosis Type 1
A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas
Treatment Overview This phase II study will evaluate the activity of sirolimus in children and adults with NF1 and inoperable plexiform neurofibromas that have the potential to cause significant morbidity.
- Trial name
- Protocol 102 (NCT00634270)
- Testing
- Sirolimus
- Where
- 9 sites in United States
- Volunteers
- 58 people
- Sponsor
- University of Alabama at Birmingham
ADPKD
The Vienna RAP Pilot Study
The purpose of this study is to evaluate the safety of a daily single oral dose of sirolimus in patients with advanced autosomal dominant polycystic kidney disease.
- Trial name
- RAP (NCT01632605)
- Testing
- Sirolimus
- Where
- Austria
- Volunteers
- 8 people
- Sponsor
- Medical University of Vienna
Kaposiform Hemangioendotheliomas, Tufted Angioma
Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies
The purpose of this study is to determine if the use of sirolimus in the treatment of children and young adults with complicated vascular anomalies will prove to be safe and provide objective response resulting in improved…
- Conditions
- Kaposiform Hemangioendotheliomas, Tufted Angioma, Capillary Venous Lymphatic Malformation, Venous Lymphatic Malformation
- Trial name
- NCT00975819
- Testing
- sirolimus
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- Denise Martin Adams
Unspecified Adult Solid Tumor, Protocol Specific
Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment
RATIONALE: Drugs used in chemotherapy, such as hydroxychloroquine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00909831
- Testing
- hydroxychloroquine, temsirolimus, electron microscopy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Leukemia, Lymphoma
T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer
RATIONALE: Giving chemotherapy, such as fludarabine and cyclophosphamide, and total-body irradiation before a donor umbilical cord blood transplant helps stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma, Plasma Cell Neoplasm
- Trial name
- NCT00602693
- Testing
- umbilical cord blood transplantation, Allopurinol, fludarabine phosphate
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Retinal Astrocytic Hamartoma
Sirolimus for Retinal Astrocytic Hamartoma
A single patient study using intravitreal Sirolimus to treat a patient with multiple retinal astrocytic hamartomas (RAH) of both eyes.
- Trial name
- NCT04707209
- Testing
- Sirolimus
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- The Hospital for Sick Children
Coronary Artery Disease
Latin America Real World Study With Inspiron Drug Eluting Stent - INSPIRON LATITUDE
Prospective, multicenter, single arm registry to monitor post-market clinical outcomes of patients treated with Inspiron Sirolimus-Eluting Stent with Biodegradable Polymer.
- Trial name
- LATITUDE (NCT03471234)
- Testing
- Angioplasty
- Where
- 2 sites in Brazil
- Volunteers
- 299 people
- Sponsor
- Scitech Produtos Medicos SA
Lymphangioleiomyomatosis (LAM)
COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC
The investigators will perform a two-center phase I trial of celecoxib (COX-2 inhibitor) administered at 200mg by mouth daily for 6 months. Up to 12 adult women with LAM will be recruited (between 4-8 at each site).
- Trial name
- COLA (NCT02484664)
- Testing
- Celecoxib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Brigham and Women's Hospital
Familial Adenomatous Polyposis
Trial of eRapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance
Patients with Familial Adenomatous Polyposis (FAP) who are undergoing endoscopic surveillance will be given Encapsulated Rapamycin (eRapa) at one of three escalating doses/schedules for 12 months with the aim of reducing polyp…
- Trial name
- NCT04230499
- Testing
- Encapsulated Rapamycin (eRapa)
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Rapamycin Holdings Inc.
Skin Neoplasms, Kidney Transplantation
Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients
The purpose of this study is to determine the effect of sirolimus on the prevention of new non-melanoma skin cancer (NMSC) in kidney transplant recipients.
- Trial name
- NCT00129961
- Testing
- sirolimus, cyclosporine or tacrolimus
- Where
- 23 sites in United States, Australia and 2 more
- Volunteers
- 86 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Kidney Transplantation
Study Investigating Rapamune For Post-Marketing Surveillance
To provide safety and effectiveness information for Rapamune during the post-marketing period as required by Korea Food and Drug Administration (KFDA) regulations in order to identify any potential drug related treatment factors…
- Trial name
- NCT00484094
- Testing
- sirolimus
- Where
- 11 sites in South Korea
- Volunteers
- 209 people
- Sponsor
- Pfizer
Endometrial Papillary Serous Carcinoma, Recurrent Endometrial Carcinoma
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors
This phase I trial is studying the side effects and best dose of giving gamma-secretase/Notch signalling pathway inhibitor RO4929097 and temsirolimus together in treating patients with advanced solid tumors.
- Conditions
- Endometrial Papillary Serous Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Renal Cell Cancer, Stage III Endometrial Carcinoma
- Trial name
- NCT01198184
- Testing
- temsirolimus, gamma-secretase/Notch signalling pathway inhibitor RO4929097, laboratory biomarker analysis
- Where
- 2 sites in Canada
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Kidney Cancer
Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer
This study is being done in 2 parts. The first part is to determine the dose of RAD001 that should be used in combination with sorafenib.
- Trial name
- NCT00392821
- Testing
- Sorafenib, RAD001
- Where
- 11 sites in United States
- Volunteers
- 78 people
- Sponsor
- SCRI Development Innovations, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.